» Articles » PMID: 28584626

MMP2 and MMP9 Associate with Crescentic Glomerulonephritis

Overview
Journal Clin Kidney J
Specialty Nephrology
Date 2017 Jun 7
PMID 28584626
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by multiple organ involvement. Lupus nephritis (LN) is a common manifestation with a wide variety of histological appearances. Matrix metalloproteinases (MMP) 2 and 9 are gelatinases capable of degrading glomerular basement membrane type IV collagen, which have been associated with LN. We examine the expression of MMP2 and MMP9 in different classes of LN. MMP2 and MMP9 expression was detected by immunohistochemistry in sections from renal biopsy specimens with class III, class IV and class V LN (total = 31), crescentic immunoglobulin A nephropathy ( = 6), pauci-immune glomerulonephritis ( = 7), minimal change disease ( = 2), mesangiocapillary glomerulonephritis ( = 7), diabetic nephropathy ( = 12) and histologically normal controls ( = 8). MMP2 and MMP9 were not expressed in all classes of LN, but were observed in LN with cellular and fibrocellular crescents. MMP2/MMP9 was expressed in cellular and fibrocellular crescents regardless of glomerulonephritis but not observed in inactive fibrous crescents or with mesangial proliferation. This suggests that MMP2 and MMP9 are involved in the development of extracapillary proliferative lesions. MMP2/MMP9 is expressed with active extracapillary proliferation. Further study is necessary to define whether the expression of MMP2/MMP9 reflects a role in glomerular repair after injury, a role in organ-level immune responses or a role as a marker of epithelialization.

Citing Articles

Matrix metalloproteinases in kidney homeostasis and diseases: an update.

Tan R, Liu Y Am J Physiol Renal Physiol. 2024; 327(6):F967-F984.

PMID: 39361724 PMC: 11687849. DOI: 10.1152/ajprenal.00179.2024.


BAG3 promotes proliferation and migration of arterial smooth muscle cells by regulating STAT3 phosphorylation in diabetic vascular remodeling.

Huang X, Guo J, Ning A, Zhang N, Sun Y Cardiovasc Diabetol. 2024; 23(1):140.

PMID: 38664681 PMC: 11046803. DOI: 10.1186/s12933-024-02216-z.


Type I IFN in Glomerular Disease: Scarring beyond the STING.

Jimenez-Uribe A, Mangos S, Hahm E Int J Mol Sci. 2024; 25(5).

PMID: 38473743 PMC: 10931919. DOI: 10.3390/ijms25052497.


Long noncoding RNA TMPO-AS1 accelerates glycolysis by regulating the miR-1270/PKM2 axis in colorectal cancer.

Jin Y, Jiang A, Sun L, Lu Y BMC Cancer. 2024; 24(1):238.

PMID: 38383342 PMC: 10880273. DOI: 10.1186/s12885-024-11964-w.


Identification of m6A-Related Biomarkers in Systemic Lupus Erythematosus: A Bioinformation-Based Analysis.

Tian Y, Tao K, Li S, Chen X, Wang R, Zhang M J Inflamm Res. 2024; 17:507-526.

PMID: 38298525 PMC: 10829513. DOI: 10.2147/JIR.S439779.


References
1.
Patel M, Clarke A, Bruce I, Symmons D . The prevalence and incidence of biopsy-proven lupus nephritis in the UK: Evidence of an ethnic gradient. Arthritis Rheum. 2006; 54(9):2963-9. DOI: 10.1002/art.22079. View

2.
Danchenko N, Satia J, Anthony M . Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006; 15(5):308-18. DOI: 10.1191/0961203306lu2305xx. View

3.
Mason L, Ravirajan C, Rahman A, Putterman C, Isenberg D . Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis?. Arthritis Rheum. 2004; 50(3):866-70. DOI: 10.1002/art.20103. View

4.
Donadio Jr J, HART G, Bergstralh E, HOLLEY K . Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus. 1995; 4(2):109-15. DOI: 10.1177/096120339500400206. View

5.
Lech M, Anders H . The pathogenesis of lupus nephritis. J Am Soc Nephrol. 2013; 24(9):1357-66. PMC: 3752952. DOI: 10.1681/ASN.2013010026. View